UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Act of 1934
Date of Report (Date of earliest event reported) –September 15, 2004
IMCOR PHARMACEUTICAL CO.
(Exact name as specified in its charter)
NEVADA | | 0-23553 | | 62-1742885 |
(State or other jurisdiction of
Incorporation or organization) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | | |
6175 Lusk Boulevard
San Diego, CA | 92121 |
(Address of principal executive offices) | (Zip Code) |
| | | | |
(858) 410-5601 |
(Registrants’ telephone number, including area code) |
| | | | |
Photogen Technologies, Inc. |
(Former name or former address, if changed since last report) |
| | | | | |
Item 8.01. OTHER EVENTS
At the current rate of spending, the Company expects to exhaust its capital by October 31, 2004. The Company is exploring a variety of options, including reducing expenses, obtaining additional capital, or selling or licensing its assets. The Company cannot provide assurances that it will be able to implement any one of these options or that, if implemented, the option would be successful.
2
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed by the undersigned hereunto duly authorized.
| IMCOR Pharmaceutical Co. |
| |
| |
| By: /s/ Taffy J. Williams | |
| Taffy J. Williams, Ph.D. |
| President and Chief Financial Officer |
| |
Dated: September 15, 2004
3
